Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis

Osteoarthritis and Cartilage(2022)10.1016/j.joca.2022.07.013Source: DataRank Database

Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis is a research paper published in Osteoarthritis and Cartilage (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.07)OA: bronzeTopics (21)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

A.C. Rogers,Valia P. Leifer,R. Edwards ORCID,Tuhina Neogi ORCID,Aleksandra M. Kostic ORCID

Live enrichment

PubMed:36414225 PMC:PMC9892279 OpenAlex:https://openalex.org/W4309765800

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: K01 AR075879

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: K24 AR070892

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: P30 AR07257

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: RO1 AR074290

NIAMS NIH HHS

Grant: P30 AR072571

NIAMS NIH HHS

Grant: P30 AR072577

NIAMS NIH HHS

Grant: R01 AR074290

National Institutes of Health

Pfizer

FWCI

1.07

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.oarsijournal.com/article/S1063458422009268/pdf

publisherhttp://www.oarsijournal.com/article/S1063458422009268/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1063458422009268?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1063458422009268?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.joca.2022.07.013

Fields of Study

Osteoarthritis Treatment and MechanismsPain Mechanisms and TreatmentsMusculoskeletal pain and rehabilitation

MeSH Terms

GabapentinCost-Effectiveness AnalysisCost-Benefit AnalysisHumansNeuralgiaQuality-Adjusted Life YearsOsteoarthritis, Knee

Keywords

GabapentinMedicineOsteoarthritisKnee painQuality-adjusted life yearPhysical therapyCost effectivenessAlternative medicinePainKnee OsteoarthritisCost-efficacy